U.S., Dec. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07272837) titled 'Impact of Semaglutide (Ozempic/Wegovy(R)) on Heart and Muscle Mass' on Nov. 26.
Brief Summary: The aim of this study is to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide. By doing so, we hope to gain a clearer understanding of how semaglutide affects muscle health and function. Our goal is to ensure the medication supports long-term well-being, particularly for people who may be at higher risk of muscle loss.
This study involves (3) in-person study visits. At each visit, participants will be asked to:
* Undergo magnetic resonance imagi...